- Home
- HRTX vs CABA Comparison
HRTX vs CABA Comparison
Compare HRTX & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | CABA |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 319.6M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HRTX | CABA |
|---|---|---|
| Price | $0.94 | $3.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.50 | ★ $14.57 |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | N/A |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.93 | $0.99 |
| 52 Week High | $2.61 | $3.78 |
Technical Indicators
Market Signals| Indicator | HRTX | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 29.12 | 54.40 |
| Support Level | N/A | $2.11 |
| Resistance Level | $1.36 | $3.34 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 2.76 | 40.91 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.